In terms of T-cell activities, there have been reports suggesting the use of increased serum levels of IL-17F [9], and MxA protein levels [12] as biomarkers for the effectiveness in IFN-β-treated MS patients. The gene discussed is IL17F; the disease is myeloid sarcoma.